

In re Application of  
Brigstock and Harding  
Application No.: 09/113,924  
Filed: July 9, 1998  
Exhibit A - Page 1

PATENT  
Attorney Docket No.: FIBRO1120-1  
(08766/003002)

**EXHIBIT A**

**CLAIMS UPON ENTRY OF THE AMENDMENT**

1. (Twice amended) An antibody or antigen binding fragment thereof which is specifically reactive with a polypeptide or an antigen fragment thereof, wherein the polypeptide is characterized as:

- a) having an amino acid sequence corresponding to the carboxy terminal amino acids of a connective tissue growth factor (CTGF) protein;
- b) binding to heparin and being eluted from heparin with about 0.8 M salt; and
- c) having a molecular weight of about 10 kDa to about 20k Da by reducing

SDS-PAGE,

wherein the polypeptide has an amino acid sequence beginning at about amino acid residue 247 or amino acid residue 248 from the N-terminus of CTGF, and has mitogenic and chemotactic activity, and

wherein the antibody or antigen binding fragment thereof is not reactive with CTGF or with platelet derived growth factor.

2. The antibody of claim 1, wherein the antibody is polyclonal.

3. The antibody of claim 1, wherein the antibody is monoclonal.

4. The antibody of claim 1, wherein the antibody is a human antibody.

5. The antibody of claim 1, wherein the antibody is a single chain antibody.

In re Application of  
Brigstock and Harding  
Application No.: 09/113,924  
Filed: July 9, 1998  
Exhibit A - Page 2

PATENT  
Attorney Docket No.: FIBRO1120-1  
(08766/003002)

6. The antibody of claim 1, wherein the antibody is a humanized antibody.
7. (Amended) The antigen binding fragment of claim 1, wherein the antigen binding fragment is an antibody fragment.